Clinical Trial
doi: 10.1016/0006-3223(90)90589-t.
Naltrexone attenuates self-injurious behavior in mentally retarded subjects
Affiliations
- PMID: 2158355
- DOI: 10.1016/0006-3223(90)90589-t
Item in Clipboard
Clinical Trial
Naltrexone attenuates self-injurious behavior in mentally retarded subjects
Biol Psychiatry.
.
Abstract
The effect of naltrexone on the frequency of self-injurious behavior (SIB) was investigated in 6 male subjects with profound mental retardation. Following a double-blind placebo-controlled crossover design, naltrexone was administered in a dose of 50 mg once daily for 3 consecutive weeks. In 2 of 5 subjects, a significant decrease of SIB frequency could be demonstrated, and in 1, a tendency to a reduction was found. No effect on duration of restrain time was found in 3 subjects. These data suggest that disturbances of the endogenous opioid systems may be involved in the pathophysiology of SIB of certain patients.
Similar articles
-
A case report of naltrexone treatment of self-injury and social withdrawal in autism.J Autism Dev Disord. 1990 Jun;20(2):169-76. doi: 10.1007/BF02284716. J Autism Dev Disord. 1990. PMID: 2189867 Clinical Trial.
-
Failure of naltrexone hydrochloride to reduce self-injurious and autistic behavior in mentally retarded adults. Double-blind placebo-controlled studies.Arch Gen Psychiatry. 1995 Sep;52(9):766-73. doi: 10.1001/archpsyc.1995.03950210060011. Arch Gen Psychiatry. 1995. PMID: 7654128 Clinical Trial.
-
An orally administered opiate blocker, naltrexone, attenuates self-injurious behavior.Am J Ment Retard. 1990 Jul;95(1):93-102. Am J Ment Retard. 1990. PMID: 2167107 Clinical Trial.
-
Self-injurious behavior: a review of the behavior and biology of self-mutilation.Am J Psychiatry. 1991 Mar;148(3):306-17. doi: 10.1176/ajp.148.3.306. Am J Psychiatry. 1991. PMID: 1847025 Review.
-
Self-restraint: a review of etiology and applications in mentally retarded adults with self-injury.Res Dev Disabil. 1991;12(1):87-95. doi: 10.1016/0891-4222(91)90024-m. Res Dev Disabil. 1991. PMID: 2017587 Review.
Cited by
-
Clinical safety of 1500 mg oral naltrexone overdose.BMJ Case Rep. 2010 Sep 7;2010:bcr0420102871. doi: 10.1136/bcr.04.2010.2871. BMJ Case Rep. 2010. PMID: 22778191 Free PMC article. Review.
-
Developmental Considerations for the Use of Naltrexone in Children and Adolescents.J Pediatr Pharmacol Ther. 2021;26(7):675-695. doi: 10.5863/1551-6776-26.7.675. Epub 2021 Sep 24. J Pediatr Pharmacol Ther. 2021. PMID: 34588931 Free PMC article.
-
Borderline personality disorder: current drug treatments and future prospects.Ther Adv Chronic Dis. 2010 Mar;1(2):59-66. doi: 10.1177/2040622310368455. Ther Adv Chronic Dis. 2010. PMID: 23251729 Free PMC article.
-
Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities.Cochrane Database Syst Rev. 2013 Apr 30;2013(4):CD009084. doi: 10.1002/14651858.CD009084.pub2. Cochrane Database Syst Rev. 2013. PMID: 23633366 Free PMC article.
-
The Potential Role of Naltrexone in Borderline Personality Disorder.Iran J Psychiatry. 2017 Apr;12(2):142-146. Iran J Psychiatry. 2017. PMID: 28659987 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
